Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Filter by
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design.
Joyce, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Frontiers in Immunology
Oct 22, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
Zalifrelimab (CTLA-4 Antagonist)
Journal for ImmunoTherapy of Cancer
Aug 8, 2019
Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution.
Florou, et al.
Frontiers in Immunology
Aug 7, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle, et al.
AGEN1327 (TIGIT Antagonist)
American Association for Cancer Research (AACR)
Mar 29
- Apr 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses.
Chand, et al.